ArticleJournal of hepatocellular carcinoma2025
Establishment and Significance of a Nomogram Prediction Model for the Risk of Hepatocellular Carcinoma in Budd-Chiari Syndrome.
Article in Journal of hepatocellular carcinoma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to identify independent risk factors for hepatocellular carcinoma (HCC) in patients initially diagnosed with Budd-Chiari syndrome (BCS) and develop a nomogram for HCC risk assessment in these patients. Patients and Methods: Retrospective analysis was conducted on clinical data from 631 newly diagnosed BCS patients (BCS group) and 50 BCS patients complicated with HCC (HCC group) admitted to the Interventional Radiology Department of the Affiliated Hospital of Xuzhou Medical University (Xuzhou, China) between October 2014 and October 2021. General data, clinical symptoms/signs, laboratory tests, imaging features, Child-Pugh classification, and Model for End-Stage Liver Disease score were analyzed. Univariate logistic regression screened risk factors (P<0.05 for multivariate inclusion), and independent risk factors were selected via backward selection (Akaike Information Criterion) to build the nomogram, validated by bootstrap method. Receiver operating characteristic (ROC) curve, calibration curve, decision curve analysis (DCA), and clinical impact curve evaluated the model. Results: Independent risk factors in the final model were disease duration [odds ratio (OR)=1.19, 95% CI=1.11-1.28], portal vein diameter (OR=140.29, 95% CI=31.63-622.22), and intrahepatic nodule formation (OR=5.03, 95% CI=2.42-10.44). Bootstrap validation showed the model's ROC area under the curve (AUC)=0.862 (95% CI=0.798-0.926), with cross-validation AUC=0.858 (95% CI=0.663-1.000, good discrimination). Calibration curves (model and internal validation) aligned with ideal status. DCA showed the nomogram had higher net benefit than extreme curves at 2-83% threshold probability. Clinical impact curve indicated threshold probability >60% identified HCC high-risk groups consistent with actual HCC occurrence. Conclusion: The independent risk factors for HCC in patients initially diagnosed with BCS were disease duration, portal vein diameter and intrahepatic nodule formation. The developed nomogram model exhibited good discrimination, accuracy and clinical applicability for the prediction of HCC risk in patients with BCS. This study, for the first time, established a nomogram for predicting the risk of HCC in patients with BCS in a single-center cohort in China, which can provide a new tool for early screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.